Effectiveness of Universal Varicella Vaccination after ten years of implementation in Tuscany (Central Italy)

Varicella vaccination is currently recommended in several European countries, including Italy. Tuscany Region introduced Universal Varicella Vaccination (UVV) in 2008, and it was later included in the Italian National Immunization Plan 2017-2019. Recently, it has also been made mandatory in Italy for school attendance. The aim of our study was to assess the effectiveness of the UVV program in preventing varicella cases and related hospitalizations in children born between 2008 and 2017, during the pre-pandemic period (2010-2019) in Tuscany (Central Italy). We applied the screening method to assess varicella vaccine effectiveness (VE) for the first and the second vaccine dose in the birth cohorts targeted by the UVV. We considered the vaccination coverage (VC) at 24 months and at 5-6 y of age, and we verified the vaccination status of each notified or hospitalized case to identify breakthrough varicella cases (BV). We assessed a VE of 84.8% (95%CI:83.5-85.9%) for at least one varicella vaccine dose and 95.7% (95% CI: 93.6-97.1%) for the second dose in preventing notifications. VE in preventing hospitalizations was 98.5% (95% CI: 96.7-99.3%) after one dose and 100% after two doses. The median time interval between the first or second vaccine dose and the onset of varicella was 34 months and 28 months, respectively. Our study demonstrated the excellent vaccine effectiveness profile of the vaccines used over a 10-y period in Tuscany, in preventing notified and hospitalized varicella cases in the target cohorts of children, confirming the health benefits of the UVV in Central Italy.

Authors

Institutions

Publication Details

Journal
Human Vaccines & Immunotherapeutics
Published
2025-12-09
DOI
https://doi.org/10.1080/21645515.2025.2595787
Primary Topic
Herpesvirus Infections and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effectiveness of Universal Varicella Vaccination after ten years of implementation in Tuscany (Central Italy)

Fabio Voller, Angela Bechini, Veronica Gallinoro, Sara Boccalini et al.
Human Vaccines & Immunotherapeutics
Herpesvirus Infections and Treatments
article

Effectiveness of Universal Varicella Vaccination after ten years of implementation in Tuscany (Central Italy)

Fabio Voller, Angela Bechini, Veronica Gallinoro, Sara Boccalini, Fabrizio Gemmi, Francesco Innocenti, Paolo Bonanni, Alessandra Ninci, Benedetta Bonito
article en

Abstract

Varicella vaccination is currently recommended in several European countries, including Italy. Tuscany Region introduced Universal Varicella Vaccination (UVV) in 2008, and it was later included in the Italian National Immunization Plan 2017-2019. Recently, it has also been made mandatory in Italy for school attendance. The aim of our study was to assess the effectiveness of the UVV program in preventing varicella cases and related hospitalizations in children born between 2008 and 2017, during the pre-pandemic period (2010-2019) in Tuscany (Central Italy). We applied the screening method to assess varicella vaccine effectiveness (VE) for the first and the second vaccine dose in the birth cohorts targeted by the UVV. We considered the vaccination coverage (VC) at 24 months and at 5-6 y of age, and we verified the vaccination status of each notified or hospitalized case to identify breakthrough varicella cases (BV). We assessed a VE of 84.8% (95%CI:83.5-85.9%) for at least one varicella vaccine dose and 95.7% (95% CI: 93.6-97.1%) for the second dose in preventing notifications. VE in preventing hospitalizations was 98.5% (95% CI: 96.7-99.3%) after one dose and 100% after two doses. The median time interval between the first or second vaccine dose and the onset of varicella was 34 months and 28 months, respectively. Our study demonstrated the excellent vaccine effectiveness profile of the vaccines used over a 10-y period in Tuscany, in preventing notified and hospitalized varicella cases in the target cohorts of children, confirming the health benefits of the UVV in Central Italy.

Human Vaccines & ImmunotherapeuticsVol. 21(1)
Azienda Ospedaliero-Universitaria Careggi (IT), Agenzia Regionale di Sanità della Toscana (IT), University of Florence (IT)
Openalex Percentile: Top 49%
Herpesvirus Infections and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.